ArticleJournal of pharmacy & bioallied sciences2025
Evaluation of microRNA Expression Profiles as Diagnostic and Prognostic Biomarkers in Oral Squamous Cell Carcinoma: A Molecular Approach.
Article in Journal of pharmacy & bioallied sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oral Squamous Cell Carcinoma (OSCC) is a leading malignancy with limited early diagnostic markers. MicroRNAs (miRNAs) have emerged as promising biomarkers due to their regulatory role in cancer pathogenesis. Objective: To evaluate the expression profiles of miR-21, miR-155, and miR-375 in OSCC and assess their diagnostic and prognostic potential. Materials and Methods: Tissue samples from OSCC patients and healthy controls were analyzed using RT-qPCR for miRNA expression. ROC analysis assessed diagnostic accuracy. Results: miR-21 and miR-155 were significantly upregulated, while miR-375 was downregulated in OSCC tissues. ROC curves showed high diagnostic value: miR-21 (Area under the curve [AUC] = 0.89), miR-155 (AUC = 0.86), and miR-375 (AUC = 0.81). Conclusion: Differential expression of selected miRNAs suggests their potential as reliable biomarkers for early OSCC detection and prognosis. Integrating miRNA profiling may enhance precision diagnostics in oral oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.